• Patient Action Center
  • Seniors Rising Now
0 Items
Patients Rising Now
  • Home
  • About
    • About Us
    • Who We Are
    • Partners and Coalitions
    • Corporate Membership
    • Corporate Members
    • Financials
  • Issues
    • 117th Congress Advocacy Scorecard
    • Legislative Positions
    • Terry’s Hot Take
    • News and Insights
    • Positions
    • Policy Supported
  • Take Action
    • Patient Action Center
    • What You Can Do
    • Advocacy Masterclass
  • Donate
Select Page
  • Home
  • About
    • About Us
    • Who We Are
    • Partners and Coalitions
    • Corporate Membership
    • Corporate Members
    • Financials
  • Issues
    • 117th Congress Advocacy Scorecard
    • Legislative Positions
    • Terry’s Hot Take
    • News and Insights
    • Positions
    • Policy Supported
  • Take Action
    • Patient Action Center
    • What You Can Do
    • Advocacy Masterclass
  • Donate

Drug Costs

How Can CMMI Follow-up on the Executive Order on Drug Pricing?

How Can CMMI Follow-up on the Executive Order on Drug Pricing?

Nov 21, 2022 | Drug Costs

By Surabhi Dangi-Garimella, Ph.D. President Biden signed an Executive Order on October 14, 2022, that tasks the HHS Secretary to engage the Innovation Center (Center for Medicare and Medicaid Innovation, CMMI) with testing healthcare payment and delivery models to...
Read more
Using March-in Rights as a Strategy for Reducing Drug Prices

Using March-in Rights as a Strategy for Reducing Drug Prices

Sep 2, 2022 | Drug Costs, Featured

By Surabhi Dangi-Garimella, Ph.D. March-in rights have been invoked again, this time with the support of Senators Elizabeth Warren (D-Mass.) and Angus King (I-Maine), and Congressman Lloyd Doggett (D-Texas). March-in rights, a provision of the Bayh-Dole regulations,...
Read more
Can Mark Cuban Deliver Cheaper RX? – Season 3 | Episode 20

Can Mark Cuban Deliver Cheaper RX? – Season 3 | Episode 20

May 23, 2022 | Drug Costs, Featured, Podcast

On this episode of the podcast, Terry and Bob discuss a new effort by entrepreneur Mark Cuban to deliver less expensive medications to patients. They also explain the ongoing baby formula shortage plaguing the country and point out how the industry’s...
Read more
Letter Supported: Importance of Orphan Drug Tax Credit for People and Families Living with Autoimmune Disease

Letter Supported: Importance of Orphan Drug Tax Credit for People and Families Living with Autoimmune Disease

Dec 15, 2021 | Drug Costs, Letters Supported

On behalf of the estimated 50 million Americans with autoimmune and immune-mediated diseases, the undersigned 64 organizations write to you regarding the importance of the Orphan Drug Tax Credit (ODTC) for people and families living with autoimmune disease and urge...
Read more
340B Drug Discount Program: Where Are We at in 2021?

340B Drug Discount Program: Where Are We at in 2021?

Dec 13, 2021 | Drug Costs, Featured

By Surabhi Dangi-Garimella, PhD In a bid to ensure access to medications for low-income and uninsured patient populations, the 340B drug discount program was launched in 1992. Designed primarily with safety-net hospitals in mind—meaning hospitals that serve a...
Read more
S2 | E42: The False Promise of Current Drug Pricing Reforms

S2 | E42: The False Promise of Current Drug Pricing Reforms

Oct 26, 2021 | Drug Costs, Featured, Podcast

On this episode of the podcast, Terry and Bob discuss the Build Back Better reconciliation bill currently being debated in Congress and highlight its drug pricing components. They explain how the highly-touted cost savings in the bill won’t actually help...
Read more
« Older Entries

Categories

  • Access
  • Advocacy
  • California
  • Comment Letters
  • Copay Accumulators
  • Copay Assistance
  • COVID-19
  • Drug Costs
  • FDA
  • Featured
  • Featured Action
  • Federal Issues
  • Health Insurance
  • Health Policy
  • ICER
  • Illinois
  • Issues
  • Letters Submitted
  • Letters Supported
  • Massachusetts
  • Medicaid
  • Medicare
  • Medicare Part D
  • News
  • Op-Ed
  • Out of Pocket Costs
  • Pharmacy Benefit Managers
  • Podcast
  • Prescription Drugs
  • Press Releases
  • Public Statement
  • QALY
  • State Issues
  • Statements
  • Step Therapy
  • Surprise Billing
  • Terry's Hot Take
  • Uncategorized
  • Value Based Insurance Design
  • Value Frameworks
  • Virtual Advocacy Chat

Tags

21st Century Cures Act 340B Access to Care Advocacy Alzheimer's Biden Administration biosimilars Cancer cms Copay Accumulators copay assistance COVID-19 Vaccine drug costs Drug Manufacturing Drug Pricing drug rebate fail first FDA Gene Therapies H.R.3 Health Insurance hospital bills HR 3708 hsa ICER Insurance design Joe Biden medicare Part B medicare part D Mental Health Nonmedical Switching open enrollment Out of Pocket Costs PBM PBMs pharmacy benefit managers Price Transparency Prior Authorization QALY Rare Disease Right to Repair Step Therapy Telehealth transparency Value Framework

Recent Posts

  • Rural Hospital Closures Further Complicates Healthcare Access in Mississippi
  • Contract Changes Leave DoD TRICARE Beneficiaries Without Pharmacy Access
  • Most Popular Podcast Episodes in 2022 From Patients Rising
  • Patients Rising Now Signs onto Letter to President on Alzheimer’s Scans
  • PRN and 17 Patient Groups Send Letter to Hill on Home Health Cuts

Get Updates In Your Inbox

Sign up for updates about our patient education, support and advocacy programs and initiatives.

YES, KEEP ME UPDATED

Patients Rising Now

We are a 501c4 group dedicated to demanding transparency in health care.  We are part of the Patients Rising suite of programs and services.

700 12th St. NW 700, Suite 700
Washington, DC 20005
202-679-8223

 

  • Privacy Policy
  • Sponsor Opportunities
  • Patients Rising
  • Patient Action Center
  • Facebook
  • Twitter
  • Instagram
All rights reserved. © 2023 Patients Rising Now